vs

Side-by-side financial comparison of AbCellera Biologics Inc. (ABCL) and American Well Corp (AMWL). Click either name above to swap in a different company.

American Well Corp is the larger business by last-quarter revenue ($55.3M vs $44.9M, roughly 1.2× AbCellera Biologics Inc.). AbCellera Biologics Inc. runs the higher net margin — -19.9% vs -45.1%, a 25.1% gap on every dollar of revenue. On growth, AbCellera Biologics Inc. posted the faster year-over-year revenue change (788.4% vs -22.1%). American Well Corp produced more free cash flow last quarter ($-17.4M vs $-44.6M). Over the past eight quarters, AbCellera Biologics Inc.'s revenue compounded faster (112.3% CAGR vs -3.6%).

AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia.

The American Tobacco Company was a tobacco company founded in 1890 by J. B. Duke through a merger between a number of U.S. tobacco manufacturers including Allen and Ginter, Goodwin & Company, and Kinney Brothers. The company was one of the original 12 members of the Dow Jones Industrial Average in 1896. The American Tobacco Company dominated the industry by acquiring the Lucky Strike Company and over 200 other rival firms. Federal Antitrust action begun in 1907 broke the company into several ...

ABCL vs AMWL — Head-to-Head

Bigger by revenue
AMWL
AMWL
1.2× larger
AMWL
$55.3M
$44.9M
ABCL
Growing faster (revenue YoY)
ABCL
ABCL
+810.5% gap
ABCL
788.4%
-22.1%
AMWL
Higher net margin
ABCL
ABCL
25.1% more per $
ABCL
-19.9%
-45.1%
AMWL
More free cash flow
AMWL
AMWL
$27.2M more FCF
AMWL
$-17.4M
$-44.6M
ABCL
Faster 2-yr revenue CAGR
ABCL
ABCL
Annualised
ABCL
112.3%
-3.6%
AMWL

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ABCL
ABCL
AMWL
AMWL
Revenue
$44.9M
$55.3M
Net Profit
$-8.9M
$-24.9M
Gross Margin
Operating Margin
-63.7%
-45.5%
Net Margin
-19.9%
-45.1%
Revenue YoY
788.4%
-22.1%
Net Profit YoY
73.9%
41.6%
EPS (diluted)
$-0.03
$-1.53

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ABCL
ABCL
AMWL
AMWL
Q4 25
$44.9M
$55.3M
Q3 25
$9.0M
$56.3M
Q2 25
$17.1M
$70.9M
Q1 25
$4.2M
$66.8M
Q4 24
$5.0M
$71.0M
Q3 24
$6.5M
$61.0M
Q2 24
$7.3M
$62.8M
Q1 24
$10.0M
$59.5M
Net Profit
ABCL
ABCL
AMWL
AMWL
Q4 25
$-8.9M
$-24.9M
Q3 25
$-57.1M
$-32.4M
Q2 25
$-34.7M
$-19.7M
Q1 25
$-45.6M
$-18.7M
Q4 24
$-42.7M
Q3 24
$-51.1M
$-43.5M
Q2 24
$-36.9M
$-49.9M
Q1 24
$-40.6M
$-72.1M
Operating Margin
ABCL
ABCL
AMWL
AMWL
Q4 25
-63.7%
-45.5%
Q3 25
-851.8%
-52.1%
Q2 25
-290.2%
-28.7%
Q1 25
-1479.6%
-45.5%
Q4 24
-60.2%
Q3 24
-1439.4%
-77.6%
Q2 24
-1276.2%
-83.4%
Q1 24
-551.5%
-126.1%
Net Margin
ABCL
ABCL
AMWL
AMWL
Q4 25
-19.9%
-45.1%
Q3 25
-637.8%
-57.5%
Q2 25
-203.3%
-27.8%
Q1 25
-1077.2%
-28.0%
Q4 24
-60.1%
Q3 24
-785.4%
-71.2%
Q2 24
-504.3%
-79.5%
Q1 24
-408.0%
-121.1%
EPS (diluted)
ABCL
ABCL
AMWL
AMWL
Q4 25
$-0.03
$-1.53
Q3 25
$-0.19
$-2.00
Q2 25
$-0.12
$-1.24
Q1 25
$-0.15
$-1.19
Q4 24
$-2.71
Q3 24
$-0.17
$-2.87
Q2 24
$-0.13
$-3.36
Q1 24
$-0.14
$-4.94

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ABCL
ABCL
AMWL
AMWL
Cash + ST InvestmentsLiquidity on hand
$128.5M
$182.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$966.9M
$235.6M
Total Assets
$1.4B
$323.8M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ABCL
ABCL
AMWL
AMWL
Q4 25
$128.5M
$182.3M
Q3 25
$83.2M
$200.9M
Q2 25
$92.4M
$219.1M
Q1 25
$159.3M
$222.4M
Q4 24
$156.3M
$228.3M
Q3 24
$126.6M
$244.6M
Q2 24
$148.3M
$276.9M
Q1 24
$123.6M
$308.6M
Stockholders' Equity
ABCL
ABCL
AMWL
AMWL
Q4 25
$966.9M
$235.6M
Q3 25
$964.0M
$254.9M
Q2 25
$1.0B
$282.6M
Q1 25
$1.0B
$294.0M
Q4 24
$1.1B
$304.8M
Q3 24
$1.1B
$336.7M
Q2 24
$1.1B
$363.9M
Q1 24
$1.1B
$408.7M
Total Assets
ABCL
ABCL
AMWL
AMWL
Q4 25
$1.4B
$323.8M
Q3 25
$1.4B
$359.4M
Q2 25
$1.4B
$388.7M
Q1 25
$1.3B
$419.5M
Q4 24
$1.4B
$436.0M
Q3 24
$1.4B
$483.0M
Q2 24
$1.4B
$507.8M
Q1 24
$1.5B
$548.4M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ABCL
ABCL
AMWL
AMWL
Operating Cash FlowLast quarter
$-34.7M
$-17.4M
Free Cash FlowOCF − Capex
$-44.6M
$-17.4M
FCF MarginFCF / Revenue
-99.4%
-31.4%
Capex IntensityCapex / Revenue
21.9%
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-174.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ABCL
ABCL
AMWL
AMWL
Q4 25
$-34.7M
$-17.4M
Q3 25
$-52.6M
$-18.8M
Q2 25
$-32.4M
$-4.7M
Q1 25
$-11.6M
$-25.1M
Q4 24
$-108.6M
$-13.4M
Q3 24
$-28.9M
$-32.4M
Q2 24
$-30.0M
$-21.8M
Q1 24
$-41.7M
$-59.8M
Free Cash Flow
ABCL
ABCL
AMWL
AMWL
Q4 25
$-44.6M
$-17.4M
Q3 25
$-61.5M
Q2 25
$-45.8M
Q1 25
$-22.2M
$-25.1M
Q4 24
$-187.0M
$-13.4M
Q3 24
$-47.4M
$-32.4M
Q2 24
$-50.1M
$-21.8M
Q1 24
$-65.8M
$-59.8M
FCF Margin
ABCL
ABCL
AMWL
AMWL
Q4 25
-99.4%
-31.4%
Q3 25
-687.0%
Q2 25
-267.9%
Q1 25
-524.0%
-37.6%
Q4 24
-3702.8%
-18.9%
Q3 24
-728.4%
-53.0%
Q2 24
-683.8%
-34.7%
Q1 24
-661.5%
-100.5%
Capex Intensity
ABCL
ABCL
AMWL
AMWL
Q4 25
21.9%
0.0%
Q3 25
99.7%
0.0%
Q2 25
78.2%
0.0%
Q1 25
251.1%
0.0%
Q4 24
1552.7%
0.0%
Q3 24
284.6%
0.0%
Q2 24
274.6%
0.0%
Q1 24
242.5%
0.1%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ABCL
ABCL

Segment breakdown not available.

AMWL
AMWL

Platform Subscription$28.8M52%
Visits$23.7M43%
Others$2.8M5%

Related Comparisons